Optimizing Intrathecal Drug Therapy for Neuropathic Pain
When traditional oral analgesics no longer control pain, some physicians are turning to alternative drug delivery methods that provide pain relief while avoiding systemic adverse effects.
Opioids
Prescribing Fewer Opioids Does Not Change Patient Satisfaction
Despite a decline in the number of opioid prescriptions issued by surgeons, patient-reported satisfaction scores have remained constant.
A New Center at Johns Hopkins Builds the Case for Psychedelic Research
This newly established center at Johns Hopkins is reinvigorating research on the potential therapeutic applications of psychedelics.
Early Access to Chiropractors, PT Linked to Decreased Long-Term Opioid Use
Patients who initially see a physical therapist or chiropractor for low back pain rather than a primary care physician are much less likely to be prescribed opioids.
Sleep Disturbances May Affect Chronic Pain Outcomes
Sleep disturbance may be associated with reduced improvements in pain interference and pain severity in patients with chronic pain, regardless of whether they are treated with opioids.
$260 Million Deal Averts First Federal Trial Over Opioids
A $260 million settlement in an opioid lawsuit was reached between two Ohio counties and four drug companies on Monday, just hours before opening arguments were to begin in a landmark federal trial over responsibility for the U.S. opioid crisis.
FDA, DEA Issue Joint Warning Letters to Illegal Online Opioid Sellers
The FDA and the Drug Enforcement Administration (DEA) have issued joint warning letters to several website operators that have been illegally selling opioid medications online.
Purdue Files for Bankruptcy Over Opioid Crisis Suits
OxyContin maker Purdue Pharma has filed for Chapter 11 bankruptcy, touching off what could be a fierce battle by dozens of states hoping to recoup billions spent fighting the opioid crisis.
Purdue Pharma Tentatively Reaches Settlement in Opioid Lawsuits
OxyContin maker Purdue Pharma has reached a tentative settlement with a coalition of states and local governments that sued the company over its role in America’s ongoing opioid crisis.
DEA Proposes Less Opioid Production, More Marijuana for Research in 2020
The Drug Enforcement Administration (DEA) is proposing a reduction in the amount of Schedule II controlled substances that can be manufactured in the US next year.
Next post in Pain
